The picture shows doctor gives a vaccine dose to a patient. — Reuters/File Moderna and Merck have said that their mRNA cancer vaccine, when combined with Merck’s widely used immunotherapy, cut the risk of melanoma death or recurrence by 42% in a large trial, potentially. ..
Experimental cancer vaccine reduces melanoma death or recurrence risk by 42%
RELATED ARTICLES
